Project Grant R01AG063857
- This federal Project Grant award of $307,000.00 from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to conduct a single, highly powered study to identify memory processes that are most sensitive to the asymptomatic, preclinical stage of Alzheimer's disease (AD) pathology. The study combines a continuous report item-location associative memory task with advanced behavioral and neural modeling to estimate subtle changes in memory precision that may differentiate healthy...
- Summary The National Institute on Aging (NIA) awarded a $2.78 million Project Grant (CFDA 93.866, Aging Research) to the University of Florida, Division of Sponsored Research, effective July 1, 2026 through June 30, 2030. The project, "Early Detection of Prodromal Brain Network Activity in Alzheimer's Disease," delivers research services focused on identifying neural signatures that distinguish early-stage Alzheimer's disease (AD) from normal aging. The primary deliverables include...
- This Project Grant award of $353,391.00, provided by the National Institute on Aging (CFDA 93.866 - Aging Research), aims to validate the use of a "Personal Learning Curve" paradigm as a sensitive marker of early memory decline related to Alzheimer's disease (AD) biomarkers in a large, diverse sample of older adults. The study seeks to determine if this digital cognitive assessment tool, which measures learning over repeated evaluations, can detect subtle AD-related memory failures...
- This Project Grant award from the National Institutes of Health's Aging Research program (CFDA 93.866) will support research to identify early transcriptional and pathological changes in brain regions vulnerable to Alzheimer's disease (AD). The $459,076 award, granted to Trustees of Boston University, will use single-nucleus RNA sequencing and targeted mass spectrometry to profile cell type-specific gene expression and tau/amyloid beta proteoforms in the transentorhinal cortex, entorhinal...
- This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to develop a new blood-based biomarker for the early detection and monitoring of Alzheimer's disease (AD). The $431,826 award, made on September 15, 2024, will fund the development of monoclonal antibodies to detect a newly discovered, neurotoxic amyloid-beta (Aβ) peptide dimer that is specific to AD pathology in the brain. The project involves the University of Wollongong conducting...
- COMTAD Project Grant Summary The University of Kansas Medical Center Research Institute, Inc. received a $589,614 Project Grant award from the National Institute on Aging (Aging Research, CFDA 93.866) effective February 1, 2026, through December 31, 2030, to develop and validate a cognitive safety monitoring system for detecting adverse side effects of anti-amyloid therapy in Alzheimer's disease treatment. The Cognitive Monitoring During Treatment for Alzheimer Disease (COMTAD) study will...
- The National Institute on Aging (NIA) awarded a $454,024 Project Grant (CFDA 93.866 - Aging Research) to the Research Foundation For Mental Hygiene, Inc. (RFMH) to conduct research on high-frequency oscillations (HFOs) as a potential biomarker for Alzheimer's disease progression. The key goals of this 2-year project are to: (1) determine if HFOs originate in the hippocampus and expand to other brain regions as Alzheimer's pathology advances, (2) assess whether disrupting HFOs can improve...
- This Project Grant award from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866) provides $320,143 to Mayo Clinic to assess the diagnostic and disease biomarker utility of blood plasma measures in patients with atypical Alzheimer's disease (AD). The 2-year project aims to determine if plasma biomarkers can differentiate atypical AD patients from healthy controls and other clinical syndromes, as well as evaluate if the plasma biomarkers correlate with clinical...
- Federal Project Grant Award Summary Advanced Brain Monitoring, Inc. received a $690,899 Project Grant awarded September 16, 2025, by the National Institute on Aging under the Aging Research program (CFDA 93.866) to validate and deploy a mobile electroencephalography (EEG) platform for objective assessment of neurocognitive deficits associated with post-acute sequelae of COVID-19 (PASC), commonly referred to as long COVID. The project, with completion targeted for May 31, 2027, focuses on...
- Project Grant Award Summary The National Institute on Aging awarded University of California, Davis a $3.42 million Project Grant (CFDA 93.866, Aging Research) on September 15, 2025, to develop and validate digital biomarkers capturing the dynamic relationship between social and cognitive health as early indicators of Alzheimer's disease and related dementias (AD/ADRD). Over the four-year project period through September 2029, the research team will address three critical gaps in understanding...
COGNITIVE CHALLENGE TO REVEAL SYSTEMIC NEUROPHYSIOLOGY BIOMARKERS IN PRE-SYMPTOMATIC ALZHEIMER?S DISEASE - THE BURDEN ON ALZHEIMER'S DISEASE (AD) IS GROWING DUE TO LONGER LIFE SPAN AND LACK OF EFFECTIVE TREATMENT. THE KNOWLEDGE GAP EXISTS FOR EARLY DETECTION AND PREDICTION OF SYMPTOM ONSET. AD PATHOLOGY (AMYLOID/TAU) AND SYNAPTIC DYSFUNCTION PRECEDES SYMPTOMS BY DECADES AND OFFERS A WINDOW OF OPPORTUNITY FOR EARLY AD DETECTION. CURRENT EARLY AD DIAGNOSIS DEPENDS ON EXPENSIVE IMAGING OR INVASIVE CEREBROSPINAL FLUID (CSF) DETECTION OF AMYLOID/TAU. OUR GOAL IS TO IDENTIFY NON-INVASIVE BIOMARKERS THAT FILL THIS GAP WITH SIMPLE TESTS BENCHMARKED TO AMYLOID/TAU BIOMARKERS. OUR EARLY STUDIES DEFINED PRE-SYMPTOMATIC AD: ELDERLY STUDY PARTICIPANTS WERE CLASSIFIED AS COGNITIVELY HEALTHY (CH) IN A MULTI-DOMAIN, NEUROPSYCHOMETRIC BATTERY. WE CLASSIFY CH PARTICIPANTS INTO TWO GROUPS BASED ON A REGRESSION-DERIVED CSF ASS42/TAU RATIO CUTOFF: CH INDIVIDUALS WITH PATHOLOGICAL RATIO (CH-PAT) OR WITH NORMAL RATIO (CH-NAT). AFTER 4 YEARS, 40% OF CH-PAT BUT NO CH-NAT INDIVIDUALS DECLINED COGNITIVELY, PROVIDING A STRONG COHORT TO EVALUATE BIOMARKERS FOR PRE- SYMPTOMATIC AD (CH-PATS) FROM NORMAL AGING (CH-NATS). AD AFFECTS MULTIPLE NERVOUS SYSTEMS. TIGHTLY RELATED TO OUR HEALTH, THE INTERACTIONS BETWEEN CONSCIOUS EXECUTIVE FUNCTION, SUBLIMINAL PROCESSING, AND AUTONOMIC REGULATION (CSA SYSTEM) RESPOND TO INTERNAL AND EXTERNAL STIMULI WITH NEURAL OSCILLATIONS THAT ARE AFFECTED BY SYNAPTIC DYSFUNCTIONS. THE CSA NEURAL OSCILLATIONS CAN BE DETECTED BY NON-INVASIVE ELECTROPHYSIOLOGICAL METHODS: EEG AND ECG, BENCHMARKED TO AMYLOID/TAU. INDIVIDUAL CSA DYSFUNCTIONS HAVE BEEN REPORTED IN THE MILD COGNITIVE IMPAIRMENT STAGE, WHILE CSA HAS NOT BEEN STUDIED IN THE PRE-SYMPTOMATIC AD. WE HYPOTHESIZED THAT CSA SYSTEM MEASUREMENTS COMBINE TO PROVIDE ROBUST BIOMARKERS FOR PRE-SYMPTOMATIC AD. ANALOGOUS TO THE STRESS TEST TO UNMASK CORONARY INSUFFICIENCY, OUR COGNITIVE CHALLENGE REVEALED CH-PATS HAD FRONTAL HYPER-ACTIVITIES WITH LOW LOAD CHALLENGE AND INSUFFICIENT COGNITIVE RESOURCES WITH HIGH LOAD CHALLENGES, HYPERRESPONSIVITY TO SUBLIMINAL INTERFERENCE, AND HYPERACTIVE AUTONOMIC REGULATION. FURTHER, COMBINED CSA BIOMARKERS IMPROVE DETECTION OF PRE-SYMPTOMATIC AD. THEREFORE, WE HYPOTHESIZE THAT NEURAL OSCILLATIONS DURING COGNITIVE CHALLENGE WILL REVEAL ALTERED EXECUTIVE FUNCTIONS IN PRE-SYMPTOMATIC AD, CORRELATE WITH COMPROMISED SUBLIMINAL PROCESSING AND AUTONOMIC NERVOUS FUNCTION, AND THEIR COMBINATION WILL IMPROVE DETECTION AND PREDICTION OF PRE-SYMPTOMATIC AD. OUR SPECIFIC AIMS WILL TEST OUR HYPOTHESIS IN A NEW COHORT AND TEST THE ABILITY OF CSA BIOMARKERS TO IDENTIFY CH- PATS AND PREDICT DECLINE IN A 2-YEAR LONGITUDINAL STUDY. ACCOMPLISHING THIS CSA APPROACH WILL PROVIDE MULTIPLE NOVEL TRANSLATIONAL BIOMARKERS TO CHARACTERIZE PRE-SYMPTOMATIC AD. THESE BIOMARKERS ARE NON-INVASIVE, BENCHMARKED TO ESTABLISHED CSF BIOMARKERS. OUR RESEARCH ADDRESSES AN IMPORTANT GAP IN PRE-SYMPTOMATIC AD DETECTION AND PREDICTION OF AD SYMPTOM ONSET.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 12/2/25 | ||
| Not listed | $64.6k | 6/10/25 | ||
| Not listed | $64.6k | 6/10/25 | ||
| Not listed | $727.0k | 3/31/25 | ||
| Not listed | $727.0k | 3/31/25 |